Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastroparesis With Diabetes Mellitus Clear all
Completed Phase 2 Interventional

Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

NCT01571297
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
30
States / cities
Dothan, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional Results available

A Scintigraphy Study in Adults With Diabetic Gastroparesis

NCT04208698
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
CIN-102 Dose 1, CIN-102 Dose 2, Placebo for CIN-102
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Jul 23, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional

Effect of Virtual Yoga in Diabetic Gastroparesis Patients

NCT07717554
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Virtual Yoga
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 3 Interventional Results available

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

NCT03285308
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
Placebo, Relamorelin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
113
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis

NCT02025725
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Transcutaneous Electroacupuncture for Gastroparesis

NCT01469286
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
TEA, Sham-TEA
Device
Lead sponsor
Transtimulation Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Jackson, Mississippi • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

NCT04026997
View directory record Official record
Conditions
Gastroparesis
Interventions
CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3, Placebo
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Chula Vista, California • Jacksonville, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Available No phase listed Expanded access

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

NCT04474990
View directory record Official record
Conditions
Gastroparesis, Diabetic Gastroparesis
Interventions
Tradipitant
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
U.S. locations
15
States / cities
Maitland, Florida • Tampa, Florida • Wauconda, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis

NCT01030341
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
CGMS and insulin pump
Device
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
San Francisco, California • Stanford, California • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Jul 23, 2026, 2:05 PM EDT
Completed No phase listed Observational

G-POEM for Treatment of Refractory Gastroparesis

NCT02732821
View directory record Official record
Conditions
Diabetic Gastroparesis, Idiopathic Gastroparesis, Gastroparesis Postoperative
Interventions
Gastric Per Oral Endoscopic Myotomy
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

NCT03426345
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
Placebo, Relamorelin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
114
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

NCT02210000
View directory record Official record
Conditions
Gastroparesis
Interventions
Placebo, Camicinal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Chandler, Arizona • Long Beach, California • Northridge, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional Results available

Rifaximin in Patients With Diabetic Gastroparesis

NCT04254549
View directory record Official record
Conditions
Crohn Disease, Diabetic Gastroparesis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Completed No phase listed Observational

Gastroparesis Registry 2

NCT01696747
View directory record Official record
Conditions
Gastroparesis, Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis

NCT02025751
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 3 Interventional Results available

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

NCT03420781
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
Placebo, Relamorelin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
161
States / cities
Athens, Alabama • Dothan, Alabama • Foley, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis

NCT00432835
View directory record Official record
Conditions
Gastroparesis
Interventions
Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
Device
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)

NCT02289846
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
IW-9179, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

NCT03268941
View directory record Official record
Conditions
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.

NCT01135186
View directory record Official record
Conditions
Gastroparesis
Interventions
sapropterin dihydrochloride
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 4 Interventional

Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis

NCT00390975
View directory record Official record
Conditions
Gastroparesis, Diabetes
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Kansas City, Kansas • Louisville, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

NCT01262898
View directory record Official record
Conditions
Gastroparesis
Interventions
GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet), Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
Concord, California • Indianapolis, Indiana • Chevy Chase, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

NCT05832151
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
CIN-102 Dose 15mg or 10mg, Placebo
Drug
Lead sponsor
CinDome Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
100
States / cities
Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients

NCT01916460
View directory record Official record
Conditions
Idiopathic Gastroparesis, Diabetic Gastroparesis
Interventions
Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)
Procedure
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Jul 23, 2026, 2:05 PM EDT